Skip to main content

Zetia News

Upfront Combo Lipid-Lowering Therapy Best for Acute Coronary Syndrome

FRIDAY, Sept. 8, 2023 – For patients with acute coronary syndromes (ACS), an upfront combination lipid-lowering therapy is significantly better than statin monotherapy for all-cause mortality,...

FDA Approves Merck’s Liptruzet (ezetimibe and atorvastatin), a New Product That Can Help Lower LDL Cholesterol

Friday, May 3, 2013 - Merck, known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has approved Liptruzet (ezetimibe and atorvastatin)...

FDA Medwatch Alert: Ezetimibe/Simvastatin (Vytorin); Simvastatin (Zocor); and Ezetimibe (Zetia)

[Posted 08/21/2008] FDA informed healthcare professionals that the Agency is investigating a report from the Simvastatin and Ezetimibe in Aortic Stenosis (SEAS) trial of a possible association...

FDA Medwatch Alert: Ezetimibe/Simvastatin (marketed as Vytorin), Ezetimibe (marketed as Zetia), and Simvastatin (marketed as Zocor)

[Posted 01/25/2008] FDA provided healthcare professionals with an early communication about an ongoing data review for Ezetimibe/Simvastatin (marketed as Vytorin), Ezetimibe (marketed as Zetia), and...

Ask a question

To post your own question to this support group, sign in or create an account.

Further information

Related condition support groups

High Cholesterol - Familial Heterozygous, High Cholesterol

Zetia patient information at Drugs.com